Arrowhead Pharmaceuticals, INC 10-Q quarterly reports

Arrowhead Pharmaceuticals reports a significant revenue decrease in its second fiscal quarter of 2026 compared to the prior year, primarily due to lower Sarepta collaboration revenue, while advancing its pipeline with new clinical trial initiations and regulatory milestones.

Arrowhead Pharmaceuticals reports a significant financial turnaround in Q1 2026, driven by key regulatory approvals, substantial milestone payments, and a new collaboration with Novartis, alongside a strengthened balance sheet.

Arrowhead Pharmaceuticals reported a significant financial turnaround and pipeline advancements, driven by its Sarepta collaboration and key regulatory progress for plozasiran.

Arrowhead Pharmaceuticals' Q2 2025 results show a significant increase in revenue and net income, primarily due to the Sarepta Therapeutics collaboration.

Arrowhead Pharmaceuticals' Q1 2025 results reveal increased R&D spending, a major collaboration with Sarepta, and progress on regulatory submissions.

Arrowhead Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in its clinical pipeline and a recent $429.3 million capital raise.

Arrowhead Pharmaceuticals reported a net loss for the second quarter of 2024, driven by decreased revenue and increased research and development expenses, while highlighting pipeline advancements and a recent capital raise.

Arrowhead Pharmaceuticals' Q1 2024 results show a net loss of $132.9 million, driven by decreased revenue and increased R&D spending, while the company continues to advance its pipeline.